மதிப்பு கட்டமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Launch prices of cancer drugs over the last decade were substantially higher in the U.S. than in similar, high-income European countries, and the gap only increased in the years after approval, according to an economic analysis. From 2009 to 2019, the median monthly treatment costs for new drugs at launch reached $11,755 in the U.S., as compared to $8,305 in Germany, $6,955 in Switzerland, and $7,355 in England, reported Kerstin N. Vokinger, MD, JD, PhD, of the University of Zurich, and colleagues. And, as described in JAMA Oncology, prices were not necessarily associated with clinical benefits in any of the surveyed countries.

United statesNorth carolinaSyed yousuf zafarKerstinn vokingerMike bassettElijahe cummingsAmerican society of clinical oncologyEuropean medicines agencyMargolis centerHealth policy at duke university in durhamUniversity of zurichYousuf zafarHealth policyDuke universityMedical oncologyClinical benefit scale